Skip to main content

Bright Minds Biosciences Inc (DRUG) Stock

Bright Minds Biosciences Inc Stock Details, Movements and Public Alerts

Stock Details

Bright Minds Biosciences Inc (DRUG), a prominent company in the healthcare sector within the biotechnology industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $87.56. Over the past 52 weeks, it has ranged between $23.18 and $92.83. This places the current price at 94.3% of its 52-week high and 277.7% above its 52-week low. Recent trading volume was recorded at 9,867. The 14-day Relative Strength Index (RSI) stands at 78.98, suggesting overbought conditions. The stock is currently trading above its 50-day moving average of $62.77 by 39.49%. Similarly, it is above its 200-day moving average of $41.75 by 109.72%. The MACD histogram is 2.06, indicating bullish momentum (MACD Line: 6.79, Signal Line: 4.72). There are currently 2 active alerts set for DRUG by users.

52-Week Range

$92.83 - $23.18

-5.68% from high · +277.74% from low

Avg Daily Volume

164,656

20-day average

100-day avg: 117,537

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Price to Book

13.45

EV/EBITDA

-0.07

EPS (TTM)

-$0.98

Beta

-0.33

Less volatile than market

How is DRUG valued relative to its earnings and growth?
Valuation data is not available for this stock.
What is DRUG's risk profile compared to the market?
With a beta of -0.33, Bright Minds Biosciences Inc is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 13.45 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

0.00%

Operating Margin

0.00%

Return on Equity

-30.80%

Return on Assets

-18.30%

Revenue Growth (YoY)

0.00%

Earnings Growth (YoY)

0.00%

How profitable and efficient is DRUG's business model?
Profitability metrics are not available for this stock.
What are DRUG's recent growth trends?
Growth data is not available for this stock.

Company Size & Market

Market Cap

$496.2M

Revenue (TTM)

$0

Revenue/Share (TTM)

$0.00

Shares Outstanding

7.09M

Book Value/Share

$7.32

Asset Type

Common Stock

What is DRUG's market capitalization and position?
Bright Minds Biosciences Inc has a market capitalization of $496.2M, classifying it as a small-cap stock (under $2B). Small-caps offer significant growth potential but come with higher volatility and risk. They can be more sensitive to economic conditions but may provide outsized returns if successful. With 7.09M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOTECHNOLOGY industry, it competes with other firms in this sector.
How does DRUG's price compare to its book value?
Bright Minds Biosciences Inc's book value per share is $7.32, while the current stock price is $87.56, resulting in a price-to-book (P/B) ratio of 11.96. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$94.08

7.45% upside potential

Analyst Recommendations

Strong Buy

2

Buy

5

Hold

0

Sell

0

Strong Sell

0

How reliable are analyst predictions for DRUG?
7 analysts cover DRUG with 100% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $94.08 implies 7.4% upside, but targets are often adjusted to follow price moves rather than predict them.
What is the Wall Street consensus on DRUG?
Current analyst recommendations:2 Strong Buy, 5 Buy, 000The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Dec 1, 2025, 02:04 AM

Technical Indicators

RSI (14-day)

78.98

Overbought

50-Day Moving Average

$62.77

39.49% above MA-50

200-Day Moving Average

$41.75

109.72% above MA-200

MACD Line

6.79

MACD Signal

4.72

MACD Histogram

2.06

Bullish

What does DRUG's RSI value tell investors?
The RSI (Relative Strength Index) for DRUG is currently 78.98, indicating the stock is in overbought territory (above 70). This suggests strong recent buying pressure that may be unsustainable. While overbought conditions can persist in strong trends, traders often watch for RSI divergences or a drop below 70 as potential sell signals. Combined with the price being above the 50-day moving average, this confirms bullish conditions.
How should traders interpret DRUG's MACD and moving average crossovers?
MACD analysis shows the MACD line at 6.79 above the signal line at 4.72, with histogram at 2.06. This bullish crossover suggests upward momentum is building. The wide histogram confirms strong momentum. The 50-day MA ($62.77) is above the 200-day MA ($41.75), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently above both MAs, confirming strength.

Indicators last updated: Dec 12, 2025, 02:45 PM

Active Alerts

Alert Condition
Price decreases by
Threshold
7%
Created
Nov 27, 2025, 03:51 PM
Alert Condition
RSI Threshold Cross
Threshold
70
Created
Nov 26, 2025, 09:47 AM

Stay Ahead of the Market with Bright Minds Biosciences Inc Alerts

Set up price alerts for Bright Minds Biosciences Inc and get notified instantly when the price hits your target. Never miss an important price movement again.